Background Oncologic treatments may lead to the development of paronychia, which may cause severe pain and dis-
Introduction
Various kinds of oncologic treatments, including traditional chemotherapy and new targeted agents, may cause cutaneous side-effects, including nail changes. For example, nail dystrophies, ridging and onycholysis are commonly observed in patients receiving docetaxel. [1] [2] [3] [4] In addition to traditional chemotherapy, epidermal growth factor receptor inhibitors (EGFRIs), including both EGFR inhibitory monoclonal antibodies and EGFR tyrosine kinase inhibitors (EGFR-TKIs), have been increasingly used for advanced solid tumours and have more favourable systemic side-effect profiles but significantly increased dermatologic adverse events (AEs) compared to cytotoxic chemotherapy. 5, 6 Paronychia is a disorder characterized by inflammation of the soft tissues around the nail. Paronychia manifests as erythema around several fingernails and toenails. This results in the formation of painful fissures, redness, swelling and non-infectious granulation. Bleeding or exudation may also lead to crust formation. 7 The incidence of paronychia in patients treated with EGFR-TKIs ranges from 4% to 67% 8 and is higher in Asian than in non-Asian populations (45.8% vs. 35.9%). 9 The onset time for this skin toxicity ranges from 4 to 8 weeks after the initiation of EGFR-TKI treatment. 7, [10] [11] [12] Even though paronychia occurs less frequently than acneiform eruption, 13 it commonly lasts longer. 5, 14 One study has shown that all patients treated with EGFRIs for more than 6 months were found to suffer from at least some type of cutaneous side-effects and that their quality of life (QoL) as evaluated by the Dermatology Life Quality Index (DLQI) was significantly impaired. 5 Diminished
QoL due to dermatologic AEs related to targeted therapies was later proven by another study using the Skindex 16 QoL instrument. 6 However, the ability to detect and grade nail changes may vary among institutions. The currently available and more commonly used paronychia grading systems include the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) and the Multinational Association of Supportive Care in Cancer (MASCC) EGFR Inhibitor Skin Toxicity Tool (MESTT). [15] [16] [17] A significant positive correlation has been found between dermatological toxicities graded by the NCI-CTCAE and MESTT. The MESTT divides nail changes related to EGFRIs into different aspects such as the nail plate, nail fold (paronychia) and digit tip, 17 while in the NCI-CTCAE grading system, paronychia is a symptom independent from other nail changes, which are nail discoloration, nail loss or nail ridging. 15, 16 Both the MESTT and NCI-CICAE grading systems include the assessment of interference of patients' activities of daily living (ADL) and management needed. In addition, the presence of different components of paronychia such as erythema, oedema, discharge and the subjective tenderness or pain is all assessed together in both grading systems. However, patients suffering from paronychia with severe discharge may show less severe erythema or oedema, while patients with severe oedema and erythema may have only minimal discharge. Besides, both the MESTT and NCI-CTCAE paronychia grading systems do not include the number of involved limbs or handedness. Therefore, we conducted a multicentre, prospective study to develop a novel scoring system focusing only on objective symptoms with separate assessments of the different components of paronychia, the number of involved limbs and handedness. The 'SPOT' scoring system
Materials and methods

Patients
The novel scoring system for paronychia related to oncologic treatments (SPOT) ( Fig. 1 ) was designed for assessing the severity of paronychia. In the SPOT, each parameter of paronychia, such as redness (R), oedema (E), discharge (D) and granulation tissue (G), was measured on a 4-point scale from 0 to 3, as defined in Table 1 with examples in Fig. 2 . Upon examination, for each parameter of the severity, we ticked the checkbox to note the involved fingers (or toes) with compatible presentation. We counted only the highest score among all involved fingers (or toes) to represent each hand (or foot). The highest scores for the different parameters could originate from different fingers (or toes). For each hand or foot, the highest possible summed score is 12, so the highest possible total score for all 4 limbs of a single patient is 48. The functioning of the thumb is one of the most essential aspects of overall hand functioning, and the great toes are important for balance, exerting more pressure than those of the five metatarsal heads and the heel. 18, 19 Therefore, we also specifically recorded the severity of each parameter of the thumbs and big toes separately in the SPOT scoring form and included these parameters into our analysis. The aforementioned severity of paronychia for each enrolled patient was measured by one of the dermatologists at each site after the given dermatologist was trained on how to use the SPOT scoring system. We analysed different components of the SPOT score, including the total SPOT score, dominant hand (DMH) score, bilateral thumbs (BTH) score, bilateral big toes (BBT) score and the summed scores for each parameter as total redness (total R), total oedema (total E), total discharge (total D) and total granulation tissue (total G). Furthermore, we also evaluated their associations with the DLQI score and VAS pain index score. 
Statistical methods
Each component (i.e. the total SPOT, DMH, BTH, BBT, total R, total E, total D and total G scores) was divided into mild, moderate and severe groups by the following methods. To distribute patients more evenly in each severity group, we sorted the score of each component by ascending order from low to high and noted the score of the 33rd and 66th percentile of the enrolled patients in this order. The scores equal to or lower than the score of the 33rd percentile patient in this arrangement were classified into the mild group, while those higher than the 66th percentile patient in this arrangement made up the severe group, and the rest (between 33rd and 66th percentile) made up the moderate group. The average scores for each component in every severity groups were calculated and analysed for their associations with the DLQI score and VAS pain index scores. The one-way ANOVA test was used to compare categorical variables, while the Tukey-Kramer test was used to compare binary or three-group variables. We used SPSS (version 18; IBM Corp, Armonk, NY) to perform statistical analyses. All actual P values are reported with 4 digits after decimal point. Only two digits after decimal point are showed for P > 0.01. A P value of less than 0.05 was considered statistically significant.
When comparing the associations of the DLQI score and VAS pain index score with the various components of the SPOT scoring system, only those components showing statistically significant differences both between the severe group and the mild group and between the severe group and moderate group were viewed as being correlated with either the DLQI score or VAS pain index score.
Results
Demographics
Ninety patients, 53 women (58.9%) and 37 men (41.1%), were enrolled ( Table 2 ). The mean age of the patients was 60.1 years and was similar among the three medical centres (NTUH: 59.5 years, NCKUH: 61.2 years and KFSYSCC: 59.8 years). The most common cancer diagnosis was lung cancer (n = 82, 91.1%), followed by colon cancer (3), oral cancer (2), nasopharyngeal carcinoma (1), breast cancer (1) and pancreatic neuroendocrine cancer (1). The most frequently encountered oncologic treatment causing paronychia in every medical centre of this study was afatinib (n = 57, 63.3%). Paronychia may also be associated with treatments of erlotinib, cetuximab, gefitinib, osimertinib/selumetinib, capecitabine/lapatinib and everolimus.
Patients in the severe paronychia group had higher DLQI scores
When comparing the SPOT scores and DLQI scores, it was found that patients with severe SPOT scores had significantly higher DLQI scores than the patients with mild or moderate SPOT scores (P = 0.0018 and 0.0015, respectively) (Fig. 3) . Similar results were also found between the severe and mild and the severe and moderate DMH score groups (P = 0.0007 and P < 0.0001, respectively), as well as between the severe and mild and the severe and moderate total granulation (total G) score groups (P = 0.0014 and P = 0.0027, respectively) (Fig. 3) . However, with respect to different total D score severity groups, statistically significant differences in the DLQI scores were only found when comparing between the severe and mild groups (P = 0.0029), but not between the severe and moderate (P = 0.14), or moderate and mild groups (P = 0.48). There was no statistically significant difference in DLQI scores in terms of the BBT, BTH, total R and total E score groups of different severities (Fig. 3) .
Patients in the severe paronychia group had higher VAS pain index scores
There was statistically significant difference in the VAS pain scores for the severe and mild paronychia groups as determined by total SPOT scores (P = 0.0030), the severe and mild paronychia groups and the severe and the moderate paronychia groups as determined by DMH scores (P = 0.0086 and 0.01, respectively), but not between the moderate and mild paronychia groups as determined by DMH (P = 0.98) scores (Fig. 4) .
Patients with severe paronychia in terms of the DMH scores were found to suffer from higher paronychia-related pain than the mild or moderate paronychia groups. However, such differences in pain scores were only found between the severe and Figure 3 Correlation of DLQI score with various SPOT scores (i.e. the total score and scores for the dominant hand, bilateral thumbs and bilateral big toes) and the four components of the SPOT score. (P value was marked with * if < 0.05).
mild groups in terms of total R, total E, total D, total G and total SPOT scores, but not between the severe and moderate or moderate and mild groups in terms of these components. The difference in VAS scores was only statistically significant between the severe and moderate groups in terms of the BTH scores (P = 0.01), but not between the severe and mild or moderate and mild BTH score groups (P = 0.05 and P = 0.77, respectively), or between any of the different BBT score severity groups.
Discussion
We found that the severity of paronychia was correlated with patients' QoL and pain index scores and that these associations could be demonstrated by the proposed new scoring system, SPOT. The total SPOT score for overall severity in the hands and feet was correlated with the DLQI scores, while the paronychia severity of the dominant hand was also correlated with both DLQI and VAS pain index scores with statistical significance. A previous study showed that patients receiving targeted cancer therapies experience significantly more cutaneous AEs than those receiving non-targeted therapies. 20 However, the impact on QoL of specific dermatologic AEs, especially those related to paronychia, was not able to be measured independently in that study. Despite several previous studies reporting paronychia related to different oncologic agents including Figure 4 Correlation of VAS pain index score with various SPOT scores (i.e. the total score and scores for the dominant hand, bilateral thumbs and bilateral big toes) and the four components of the SPOT score. (P value was marked with * if < 0.05).
most EGFRIs, 5, [11] [12] [13] 21 a detailed discussion about paronychia severity with various components and their association with QoL and pain is still lacking. It has been shown that no statistically significant difference can be found on the impact of QoL between patients with nail disorders involving only fingernails or only toenails. 22 Thus, fingernails and toenails were hypothesized to have similar impacts on the QoL of patients with paronychia. The current study provides further information that severe paronychia of the bilateral thumbs or bilateral big toes does not have a greater impact on DLQI scores. However, a significantly higher VAS pain score related to severe paronychia of the bilateral thumbs, but not that of the big toes, indicated that thumbs may play a more important role than big toes in the experience of tenderness.
Compared to the impact on QoL caused by other nail disorders or dermatological diseases, we found that the average DLQI score (13.1) in patients with paronychia related to oncologic treatments was much higher than those of patients with psoriatic nails (4.44), 23 Thus, paronychia related to oncologic treatments may cause significantly impaired QoL in cancer patients. Furthermore, only the severe paronychia group exhibited significantly higher impacts in terms of pain scores and QoL scores, indicating the importance of treating patients' paronychia in the early stage and maintaining it at mild-to-moderate severity, as well as the importance of managing the pain induced by paronychia of the dominant hand. We also found that the granulation tissue (total G score) of paronychia interferes significantly with patients' QoL. A statistically significant difference in DLQI scores was also observed between the severe and mild total D score groups. The above findings suggest that the treatment of paronychia to improve patient's QoL should focus on reducing granulation tissue and discharge.
The DLQI is the most commonly used QoL instrument in randomized controlled trials of psoriasis. 34 It has been shown to correlate with patients' psoriasis area and severity index (PASI) change during the treatments 35 and thus is now considered to be a triage tool for psoriasis management strategies in the UK. 36 Futures studies are needed to validate the clinical application of both DLQI scores and SPOT scores to demonstrate a correlation between changes in the DLQI and SPOT scores during the treatment process for patients with paronychia related to oncologic treatments. In addition, a patient-reported outcomes (PRO) questionnaire is also needed to measure the subjective treatment responses.
Limitations
This study was an observational study with a limited number of cases in one country. The impact of nail disorders on patients' quality of life, including their emotions and social life, may vary significantly between countries due to cultural differences. 37, 38 The current study may thus be somewhat limited in that it is only representative of patients with a similar cultural background. Educational levels and living environments may also contribute to different impacts of paronychia on DLQI scores. A previous study showed that patients with higher educational levels and people living in towns or cities were more emotionally and socially affected by onychomycosis. 39 It has also been shown that the DLQI has limited applicability in Chinese patients with skin disease because the Chinese version of the DLQI, when examined with Rasch analysis, failed to fulfil the proper psychometric requirements. 40 The SPOT scoring system should thus be further validated in large multinational studies.
Conclusion
The SPOT scoring system demonstrated the association of the severity of paronychia with DLQI and pain index scores. It may therefore be useful in clinical practice and future studies.
